Merck's undervalued stock presents growth opportunities with Keytruda and promising pipeline drugs, making it a Buy despite ...

As a wave of patent expirations encroaches upon many of the world’s top drugmakers, companies will need to be diligent in ...

Some critics described Medicare price negotiation as a good first step but say they want Congress to do more to rein ... on ...

it does indicate how many patents are needed in a single territory and is therefore relevant to the kind of policy-related analysis we have undertaken. In 2002, Ernst & Young reported that the ...

MRK Chart Does that mean investors should stay away from Merck ... It remains to be seen how many of them would actually switch to the subcutaneous version, whose patent exclusivity would extend ...

Its top-selling treatment, Keytruda, will lose patent protection in a few years ... and where it doesn't already have them, ...

This fascinating insight confirms that patents do indeed shape the components many riders use daily and which have been raced at the top level. SRAM had to find a solution to bring eTap to market ...

In the last year, many Merck & Co., Inc. (NYSE ... their decisions solely on what the directors of a company have been doing, we do think it is perfectly logical to keep tabs on what insiders ...

In reality, you should also not think in terms of a single patent drawing or illustration, but rather in terms of however many patent drawings are necessary in order to demonstrate what you have ...

The Invent + Patent System™ is an innovative approach to the patent process that will assist you in drafting your own Provisional Patent Application. This is a 100% Do ... many of us may have ...